MicroRNAs in urine are not biomarkers of multiple myeloma
Language English Country England, Great Britain Media electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
26399230
PubMed Central
PMC4581458
DOI
10.1186/s12952-015-0035-7
PII: 10.1186/s12952-015-0035-7
Knihovny.cz E-resources
- MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- MicroRNAs genetics urine MeSH
- Multiple Myeloma diagnosis genetics urine MeSH
- Biomarkers, Tumor urine MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Gene Expression Profiling methods MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- MicroRNAs MeSH
- Biomarkers, Tumor MeSH
BACKGROUND: In this study, we aimed to identify microRNA from urine of multiple myeloma patients that could serve as a biomarker for the disease. RESULTS: Analysis of urine samples was performed using Serum/Plasma Focus PCR MicroRNA Panel (Exiqon) and verified using individual TaqMan miRNA assays for qPCR. We found 20 deregulated microRNA (p < 0.05); for further validation, we chose 8 of them. Nevertheless, only differences in expression levels of miR-22-3p remained close to statistical significance. CONCLUSIONS: Our preliminary results did not confirm urine microRNA as a potential biomarker for multiple myeloma.
Central European Institute of Technology Masaryk University Brno Czech Republic
Department of Clinical Hematology University Hospital Brno Brno Czech Republic
Department of Hematology and Oncology Kantonsspital St Gallen St Gallen Switzerland
Department of Internal Medicine Hematooncology University Hospital Brno Brno Czech Republic
Department of urologic oncology Masaryk Memorial Cancer Institute Brno Czech Republic
See more in PubMed
Rajkumar SV. Multiple Myeloma. Curr Probl Cancer. 2009;33:7–64. doi: 10.1016/j.currproblcancer.2009.01.001. PubMed DOI PMC
Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S A. 2008;105:12885–12890. doi: 10.1073/pnas.0806202105. PubMed DOI PMC
Turchinovich A, Weiz L, Langheinz A, Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Res. 2011;39:7223–7233. doi: 10.1093/nar/gkr254. PubMed DOI PMC
Lionetti M, Agnelli L, Mosca L, Fabris S, Andronache A, Todoerti K, et al. Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles. Genes Chromosomes Cancer. 2009;48:521–531. doi: 10.1002/gcc.20660. PubMed DOI
Ahmad N, Haider S, Jagannathan S, Anaissie E, Driscoll JJ. MicroRNA theragnostics for the clinical management of multiple myeloma. Leukemia. 2014;28:732–738. doi: 10.1038/leu.2013.262. PubMed DOI
Jones CI, Zabolotskaya MV, King AJ, Stewart HJ, Horne GA, Chevassut TJ, et al. Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma. Br J Cancer. 2012;107:1987–1996. doi: 10.1038/bjc.2012.525. PubMed DOI PMC
Yoshizawa S, Ohyashiki JH, Ohyashiki M, Umezu T, Suzuki K, Inagaki A, et al. Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders. Blood Cancer J. 2012;2 doi: 10.1038/bcj.2011.51. PubMed DOI PMC
Kubiczkova L, Kryukov F, Slaby O, Dementyeva E, Jarkovsky J, Nekvindova J, et al. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica. 2014;99:511–518. doi: 10.3324/haematol.2013.093500. PubMed DOI PMC
Mestdagh P, Hartmann N, Baeriswyl L, Andreasen D, Bernard N, Chen C, et al. Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study. Nat Methods. 2014;11:809–815. doi: 10.1038/nmeth.3014. PubMed DOI
Redova M, Poprach A, Nekvindova J, Iliev R, Radova L, Lakomy R, et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med. 2012;10:55. doi: 10.1186/1479-5876-10-55. PubMed DOI PMC
Scheffer AR, Holdenrieder S, Kristiansen G, von Ruecker A, Müller SC, Ellinger J. Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer? World J Urol. 2014;32:353–358. doi: 10.1007/s00345-012-1010-2. PubMed DOI
Mlcochova H, Hezova R, Stanik M, Slaby O. Urine microRNAs as potential noninvasive biomarkers in urologic cancers. Urol Oncol. 2014;32:41. doi: 10.1016/j.urolonc.2013.04.011. PubMed DOI
Fišerová B, Kubiczková L, Sedlaříková L, Hájek R, Ševčíková S. The miR-29 family in hematological malignancies. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014 Jul 4. doi: 10.5507/bp.2014.037. [Epub ahead of print]. PubMed
Slabý O, Svoboda M. [MicroRNA in oncology]. Praha: Galén; 2012. ISBN 9788072625871 807262587X.
Sevcikova S, Kubiczkova L, Sedlarikova L, Slaby O, Hajek R. Serum miR-29a as a marker of multiple myeloma. Leuk Lymphoma. 2012;54:189–191. doi: 10.3109/10428194.2012.704030. PubMed DOI
Schena FP, Serino G, Sallustio F. MicroRNAs in kidney diseases. New promising biomarkers for diagnosis and monitoring. Nephrol Dial Transplant. 2014;29:755–763. doi: 10.1093/ndt/gft223. PubMed DOI
Chen L, Li C, Zhang R, Gao X, Qu X, Zhao M, et al. miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma. Cancer Lett. 2011;309:62–70. doi: 10.1016/j.canlet.2011.05.017. PubMed DOI
Tao J, Wu D, Li P, Xu B, Lu Q, Zhang W. microRNA-18a, a member of the oncogenic miR-17-92 cluster, targets Dicer and suppresses cell proliferation in bladder cancer T24 cells. Mol Med Rep. 2012;5:167–172. PubMed
Nakada C, Matsuura K, Tsukamoto Y, Tanigawa M, Yoshimoto T, Narimatsu T, et al. Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. J Pathol. 2008;216:418–427. doi: 10.1002/path.2437. PubMed DOI
